Pricing Log in Create free account

Castle Biosciences, Inc. (CSTL) vs Exagen Inc. (XGN)

Castle Biosciences, Inc. and Exagen Inc. are both Diagnostics & Research companies. Castle Biosciences, Inc. is the larger, with a market value of $1.0B against $184.1M — 5.6× the size. Exagen Inc. grew revenue faster over the last twelve months: 20.8% against 9.78%. Castle Biosciences, Inc. has the higher net margin (−6.10% vs −26.6%) and the higher return on invested capital (−3.63% vs −68.3%). Across the 18 metrics below, Castle Biosciences, Inc. leads on 14 and Exagen Inc. on 4.

Valuation

Metric CSTL XGN Diagnostics & Research median
P/E n/m n/m 34.52
P/S 2.77 2.56 4.24
P/B 2.19 14.88 3.42
Price to free cash flow 262.33 n/m 33.51
EV/EBITDA n/m n/m 23.44
EV/Sales 2.10 2.55 5.18
Earnings yield (2.25%) (10.77%) (1.50%)
Free cash flow yield 0.38% (4.17%) 0.00%

Profitability

Metric CSTL XGN Diagnostics & Research median
Gross margin 77.07% 58.64% 48.32%
Operating margin (7.43%) (18.58%) (5.68%)
Net margin (6.10%) (26.61%) (4.10%)
Free cash flow margin 1.06% (10.66%) 0.00%
Return on equity (4.87%) (113.82%) 0.00%
Return on assets (4.03%) (34.19%) (6.05%)
Return on invested capital (3.63%) (68.33%) 0.00%

Growth

Metric CSTL XGN Diagnostics & Research median
Revenue growth (TTM) 9.78% 20.83% 8.99%
EPS growth (last fiscal year) (233.87%) (12.05%) 20.36%
Revenue growth, 5-year CAGR 40.60% 9.66% 7.30%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CSTL XGN Diagnostics & Research median
Debt to equity 0.01 2.00 0.01
Current ratio 5.28 3.18 2.27
Net debt to EBITDA 46.20 0.68 0.68

Dividend

Metric CSTL XGN Diagnostics & Research median
Dividend yield — — 0.67%
Payout ratio — — 0.20

Size

Metric CSTL XGN Diagnostics & Research median
Market cap 1.04b 184.11m 2.22b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack